跳到正文
原文
Endpoints News 生物医药· Elizabeth Cairns·· 2026-09-30AI 评分50

EASD26会议:Lilly的三重激动剂Retatrutide使60%患者体重降至肥胖阈值以下

#EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold

AI 导读

Eli Lilly在EASD26会议上公布数据,其三重激动剂retatrutide帮助同时患有肥胖症和2型糖尿病的患者体重最多减少18.8%。

正文

MI­LAN — Eli Lil­ly said Tues­day that its triple ag­o­nist re­ta­tru­tide helped pa­tients with both obe­si­ty and type 2 di­a­betes lose up to 18.8% of their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news